A microRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma

Zhang, Li; Xiang, Zuo-Lin; Zeng, Zhao‐Chong; Fan, Jia; Tang, Zhao–You; Zhao, Xiaomei

doi:10.18632/oncotarget.6534

Cited by 21 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-145 has also been suggested as one of the predictive factors for the early prediction of lymph node metastasis in patients with hepatocellular carcinoma (6). Although previous studies report miR-145 is one of the most down-regulated miRNAs in both superficial Ta-T1 bladder tumors and invasive T2–T4 tumors with no significant difference between these two stages of human BC (39–42), the correlation of miR-145 expression with BC with lymph node metastatic status has never been explored.…”

Section: Disscussionmentioning

confidence: 99%

“…However, it has recently been found that tumor-specific deletion of miR-145 in an autochthonous mouse model of lung adenocarcinoma did not affect tumor development, and that stromal expression of miR-145 promotes neoangiogenesis in lung cancers (5), thus arguing against the delivery of this miRNA as an agent in cancer therapeutics. Moreover, miR-145 displays dramatic up-regulation in hepatocellular carcinoma and colorectal cancers with lymph node metastasis in comparison to those without lymph node metastasis (6, 7), suggesting that miR-145 may promote lymph node metastasis of cancer, or it may even play an oncogene role in metastatic cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145

Jiang

Huang

et al. 2017

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Although miR-145 is the most frequently down-regulated miRNA in bladder cancer (BC), its exact stage-association and downstream effector have not been defined. Here, we found that miR-145 was upregulated in human BC patients with lymph node metastasis and in metastatic T24T cell line. Forced expression of miR-145 promoted anchorage-independent growth of T24T cells accompanied by the down-regulation of forkhead box class O1 (FOXO1). In contrast, in non-metastatic T24 cells, miR-145 overexpression inhibited cell growth with upregulation of FOXO1 and the knockdown of FOXO1 abolished the miR-145-mediated inhibition of cell growth. Mechanistic studies revealed that miR-145 directly bound to and attenuated 3′UTR activity of foxo1 mRNA in both T24 and T24T cells. Interestingly, miR-145 suppressed STAT3 phosphorylation at Tyr705 and increased foxo1 promoter transcriptional activity in T24 cells, but not in T24T cells, suggesting a role of STAT3 in the divergent responses to miR-145. Supporting this was our finding that STAT3 knockdown mimicked miR-145-mediated upregulation of FOXO1 in T24T cells and inhibition of anchorage-independent growth. Consistently, ectopic expression of miR-145 promoted tumor formation of xenograft T24T cells, whereas such promoting effect became inhibitory due to specific knockdown of STAT3. Together, our findings demonstrate the stage-specific association and function of miR-145 in BCs, and provide novel insights into the therapeutic targeting of miR-145.

show abstract

Section: Disscussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145

Jiang

Huang

et al. 2017

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…However, the evaluation results of AUS may vary between examiners, and the overall accuracy of AUS remains controversial, especially in low‐burden lymph node disease. A miRNA‐based prediction model for lymph node metastasis in hepatocellular carcinoma has been developed, which can effectively and accurately classify patients into groups with low risk or high risk of developing lymph node metastasis . Our study here first evaluated the usefulness of miRNAs signature as an effective molecular approach for the preoperative diagnosis of ALN metastases in EIBC.…”

Section: Discussionmentioning

confidence: 99%

“…A miRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma has been developed, which can effectively and accurately classify patients into groups with low risk or high risk of developing lymph node metastasis. 28 Our study here first evaluated the usefulness of miRNAs signature as an effective molecular approach for the preoperative diagnosis of ALN metastases in EIBC. The results suggest that the evaluation of nine miRNAs expression could be an important tool for the management of EIBC patients, The y axis displays the net benefit, which was calculated by minusing the proportion of false-positive patients from the proportion of true positive patients, weighting by the relative harm of giving up treatment compared to the negative effects by unnecessary treatment.…”

Section: Discussionmentioning

confidence: 99%

Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical‐related features for axillary lymph node metastasis in early‐stage invasive breast cancer

Xie

Tan

Chen

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

More than half patients who undergo axillary lymph node (ALN) surgery are ALN negative in early-stage invasive breast cancer (EIBC). Thus, to avoid excessive treatment, we aim to establish and validate a novel nomogram model for the preoperative diagnosis of ALN status in patients with EIBC. In total, 864 patients with EIBC from two independent centers were enrolled in our study. For the discovery set, miRNAs expression profiling with functional roles in ALN metastasis was discovered by microarray analysis and validated by quantitative polymerase chain reaction (PCR). For the training and validation cohorts, we used PCR to quantify miRNAs expression in a model development cohort and assessed miRNAs signature in an internal validation cohort and external independent validation cohort. Multivariable logistic regression analyses were used to establish a nomogram model for the likelihood of ALN metastasis from miRNAs signature and clinical variables. A signature of nine-miRNA was significantly associated with ALN status. The predictive ability of our nomogram that included miRNAs signature and clinical-related variables (age, tumor size, tumor location and axillary ultrasound-reported ALN status) was significantly greater than a model that only considered clinical-related factors (concordance index: 0.856, 0.796) and also performed well in the two validation cohorts (concordance index: 0.841, 0.747). Our nomogram is a reliable prediction method that can be conveniently used to preoperatively predict ALN status in patients with EIBC. Therefore, after further confirmation in prospective and multicenter clinical trial, omission of axillary surgery may be feasible for some patients with EIBC in the future.

show abstract

“…17,18 Liver biopsy was also reported to increase the risks for distant metastasis and reduce survival. 19 Thus, a noninvasive method which can predict the probability of liver metastasis of patients with PDAC is needed. In this study, we have developed and validated the predictive nomograms using the SEER dataset, which demonstrated significant discrimination and calibration to provide evidence-based and individualized estimation for the probabilities of liver metastasis in patients with PDAC.…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of a Nomogram to Predict Liver Metastasis in Patients with Pancreatic Ductal Adenocarcinoma: A Large Cohort Study

He¹,

Zhong

Cai³

et al. 2018

SSRN Journal

View full text Add to dashboard Cite

These authors contributed equally to this workBackground: Few studies have explored the relationship between clinicopathological factors of patients with pancreatic ductal adenocarcinoma (PDAC) and liver metastasis. The aim of this study was to develop and validate a nomogram to predict liver metastasis in patients with PDAC. Patients and methods: Patients diagnosed with PDAC between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively collected. The nomogram was established based on a logistic regression model. The precision of the nomogram was evaluated and compared using concordance index (C-index), and the area under receiver operating characteristic curve (AUC). The clinical use of nomogram was evaluated by making use of a decision curve analysis (DCA). Results: A total of 12,644 eligible patients, which were randomly divided into training (n=9,483) and validation cohorts (n=3,161), were included in this study. The nomograms, which were established on the basis of independent predictors, were well calibrated, and demonstrated good discriminative ability, with C-indexes of 0.784 for the training cohort and 0.790 for validation cohort. The values of AUC for training and validation cohort were 0.792 and 0.800, respectively. When other sites of distant metastases were included into this predictive system, the new predictive model demonstrated a better discriminative ability and greater net benefit in predicting liver metastasis in patients with PDAC in both the training and validation cohorts. Conclusion: Nomograms were constructed to predict liver metastasis in patients with PDAC. Validation revealed excellent discrimination and calibration of the nomograms, suggesting that the nomograms were well calibrated and could serve to improve the prediction of the risks of liver metastasis which can be used to guide the management of patients with PDAC.

show abstract

A microRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma

Cited by 21 publications

References 35 publications

Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145

Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145

Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical‐related features for axillary lymph node metastasis in early‐stage invasive breast cancer

Development and Validation of a Nomogram to Predict Liver Metastasis in Patients with Pancreatic Ductal Adenocarcinoma: A Large Cohort Study

Contact Info

Product

Resources

About